CRBP (Corbus Pharmaceuticals Holdings) Long-Term Capital Lease Obligation : $2.05 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Long-Term Capital Lease Obligation?

Corbus Pharmaceuticals Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.05 Mil.

Corbus Pharmaceuticals Holdings's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 ($2.86 Mil) to Jun. 2024 ($2.46 Mil) and declined from Jun. 2024 ($2.46 Mil) to Sep. 2024 ($2.05 Mil).

Corbus Pharmaceuticals Holdings's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($5.96 Mil) to Dec. 2022 ($4.68 Mil) and declined from Dec. 2022 ($4.68 Mil) to Dec. 2023 ($3.24 Mil).

Corbus Pharmaceuticals Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Long-Term Capital Lease Obligation Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

8.10

7.09

5.96

4.68

3.24

Corbus Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.61	3.24	2.86	2.46	2.05

Corbus Pharmaceuticals Holdings (NAS:CRBP) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Corbus Pharmaceuticals Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

0SZI:UK 3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Executives

Yuval Cohen	director, officer: Chief Executive Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran	officer: Chief Financial Officer	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Yong Ben	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian	officer: Chief Commercial Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachael Louise Brake	officer: Chief Scientific Officer	21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White	officer: Chief Medical Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia	officer: Chief Operating Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman	director	15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Avery W Catlin	director	241 CENTRAL STREET, HINGHAM MA 02043